La chaîne d'options affiche les données clés des options sur actions de AtriCure à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour AtriCure..

AtriCure (NASDAQ:ATRC) Stock, Chaîne d'Options

ATRICURE INC

AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

AtriCure Inc

WIIM

ATRC

AtriCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance above estimates.

Needham analyst Mike Matson maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and raises the price target from $44 to $45.

News

Price Target

Analyst Ratings

Needham Maintains Buy on AtriCure, Raises Price Target to $45

Shares of LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) rose sharply in pre-market trading after the company reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/LC/earnings">sales results</a>.
LendingClub reported a strong second-quarter performance, with a 156% increase in net income. The company's second-quarter revenue and net income growth outperformed the previous year by 33% and 32%, respectively.
LendingClub shares surged 23.2% to $16.20 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Fundamental Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGF#NASDAQ">FGF</a>) shares gained 60.9% to $34.60 in pre-market trading. Fundamental Global raised $200 million in private placement to launch Ethereum Treasury strategy on ETH&#8217;s 10th anniversary.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) rose 53.1% to $5.74 in pre-market trading after gaining 18% on Tuesday.</li>
<li>Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) climbed 47.6% to $1.86 in pre-market trading after gaining 39% on Tuesday.</li>
<li>STAK Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAK#NASDAQ">STAK</a>) shares jumped 39.7% to $2.34 in pre-market trading after falling 18% on Tuesday.</li>
<li>Tigo Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) surged 31.9% to $1.60 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter sales guidance above estimates.</li>
<li>OceanPal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) gained 28.2% to $0.18 in pre-market trading after dipping 18% on Tuesday.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) gained 21.1% to $8.16 in pre-market trading.</li>
<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) rose 10.5% to $35.03 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) gained 9.7% to $17.36 in pre-market trading after surging 14% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) dipped 31.6% to $0.0347 in pre-market trading after falling 12% on Tuesday.</li>
<li>Cardiff Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) declined 25.7% to $2.46 in pre-market trading after the company announced second-quarter earnings.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) fell 18.8% to $0.9659 in pre-market trading. ScanTech AI Systems shares jumped 78% on Tuesday after the company announced it will offer its technology through the TIPS contract it entered with Creeksource Consulting.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) dipped 16.5% to $3.24 in pre-market trading after falling over 8% on Tuesday. AEHL signed a $50 million financing agreement to launch a Bitcoin acquisition plan.</li>
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) declined 15.3% to $0.1850 in pre-market trading after gaining 44% on Tuesday.</li>
<li>China Natural Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHNR#NASDAQ">CHNR</a>) shares tumbled 10.5% to $3.97 in pre-market trading after gaining 5% on Tuesday.</li>
<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) fell 10.2% to $41.96 in pre-market trading following quarterly results.</li>
<li>Global Interactive Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GITS#NASDAQ">GITS</a>) fell 8.8% to $2.19 in pre-market trading after declining 7% on Tuesday.</li>
<li>SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) shares fell 7.8% to $20.64 in pre-market trading after the company reported the pricing of public offering of common stock.</li>
<li>Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) fell 6.6% to $142.55 in pre-market trading after the company posted fourth-quarter results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46684052/jim-cramer-prefers-this-financial-stock-over-brighthouse-financial">Jim Cramer Prefers This Financial Stock Over Brighthouse Financial</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHL

CAPR

CHNR

CRDF

New Oriental Education & Technology Group

GITS

HCTI

REPL

SISI

SOFI

SRPT

STAI

STAK

TYGO

Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock increased by 27.1% to $1.27 during Tuesday's after-market session. The company's market cap stands at $1.5 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 16.77% to $1.81. The market value of their outstanding shares is at $181.9 million. </li>
<li>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) stock rose 10.36% to $35.02. The company's market cap stands at $1.6 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares increased by 10.26% to $0.79. The company's market cap stands at $16.6 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares moved upwards by 9.93% to $0.99. The market value of their outstanding shares is at $38.4 million. </li>
<li>Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) stock moved upwards by 8.44% to $0.36. The market value of their outstanding shares is at $14.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) shares fell 28.7% to $2.36 during Tuesday's after-market session. The company's market cap stands at $248.1 million. The company's, Q2 earnings came out today. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) stock fell 11.34% to $3.13. The company's market cap stands at $233.0 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock declined by 10.23% to $4.48. The company's market cap stands at $102.9 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares declined by 9.94% to $2.9. The company's market cap stands at $17.5 million. As per the press release, Q2 earnings came out 4 days ago. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 7.48% to $0.43. The market value of their outstanding shares is at $3.6 million. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock decreased by 6.09% to $1.08. The market value of their outstanding shares is at $33.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ATNF

DYAI

LPTX

Larimar Therapeutics, Inc. - Common Stock

LRMR

MBRX

NIVF

NTHI

SLRX

12 Health Care Stocks Moving In Tuesday's After-Market Session

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) raises FY2025 Adj EPS guidance from $(0.55)-$(0.50) to $(0.39)-$(0.34) vs $(0.53) analyst estimate. Raises FY2025 sales outlook from $517.000 million-$527.000 million to $527.000 million-$533.000 million vs $522.898 million estimate.

Guidance

AtriCure Raises FY2025 Adj EPS Guidance from $(0.55)-$(0.50) to $(0.39)-$(0.34) vs $(0.53) Est; Raises FY2025 Sales Guidance from $517.000M-$527.000M to $527.000M-$533.000M vs $522.898M Est

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 88.1 percent. This is a 88.24 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $136.139 million which beat the analyst consensus estimate of $130.171 million by 4.58 percent. This is a 17.09 percent increase over sales of $116.269 million the same period last year.

Earnings

Earnings Beats

AtriCure Q2 Adj. EPS $(0.02) Beats $(0.17) Estimate, Sales $136.139M Beat $130.171M Estimate

ACGL

ALKS

APAM

ARCC

ASTL

AUDC

BAFN

BAND

BBNX

BKNG

BRSL

BRSP

CAKE

CARR

CBRE

CECO

CHCT

CMPR

CNOB

CSTM

CVEO

CVLT

DHIL

ENIC

EXLS

FCPT

FELE

FIBK

FRSH

FTAI

FYBR

GATX

HOUS

HUBB

ILPT

INCY

JBGS

JBLU

KNSA

LOGI

LSTR

LXFR

MARA

MDLZ

NEOG

NMIH

NWBI

Earnings Scheduled For July 29, 2025

Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without a preoperative Afib diagnosis
AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally.
LeAAPS is a prospective, randomized, blinded, superiority, investigational device exemption (IDE) trial evaluating the AtriClip&#xAE; LAA Exclusion System for the prevention of ischemic stroke and systemic arterial embolism in cardiac surgery patients without a history of Afib—a large and often underserved population at elevated risk for these events. It is estimated that well over one million cardiac surgery procedures occur annually and more than 70% of these patients have no history of Afib before surgery.
AtriCure first entered the LAA management market with FDA 510(k) clearance of the AtriClip System in 2010. Today, AtriClip devices are the most widely used LAA management device worldwide. The company plans to use LeAAPS data to support an expanded indication for stroke prevention in patients at elevated risk of ischemic stroke.

AtriCure Completes Enrollment In Left Atrial Appendage Exclusion For Prophylactic Stroke Reduction Clinical Trial

AtriCure shares are trading lower after the company reported Q1 financial results. Additionally, UBS cut its price target on the stock from $60 to $58.

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $60 to $58.

UBS Maintains Buy on AtriCure, Lowers Price Target to $58

JMP Securities analyst Daniel Stauder reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Market Outperform and maintains $60 price target.

Reiteration

JMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target

Ratings for AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for AtriCure, revealing an average target of $52.5, a high estimate of $66.00, and a low estimate of $44.00. Marking an increase of 2.94%, the current average surpasses the previous average price target of $51.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1746018071_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of AtriCure's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$66.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Lilia-Celine Lozada</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtriCure compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into AtriCure's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ATRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AtriCure analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into AtriCure's Background</h2>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
<h3>AtriCure: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: AtriCure's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.64%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: AtriCure's net margin is impressive, surpassing industry averages. With a net margin of -12.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AtriCure's ROE stands out, surpassing industry averages. With an impressive ROE of -3.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.54%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.17, AtriCure adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

14 Analysts Assess AtriCure: What You Need To Know

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) price target from $383 to $384. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Visa shares closed at $341.52 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/V/analyst-ratings">view this stock</a>.</li>
<li>TD Securities cut the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $102 to $90. TD Securities analyst Agnes Lim maintained a Buy rating. Starbucks shares closed at $84.85 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">view this stock</a>.</li>
<li>Needham cut AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) price target from $51 to $44. Needham analyst Mike Matson maintained a Buy rating. AtriCure shares closed at $34.65 on Tuesday. See how other <a href="https://www.benzinga.com/quote/ATRC/analyst-ratings">analysts view this stock</a>.</li>
<li>DA Davidson cut the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $170 to $155. DA Davidson analyst Tom White upgraded the stock from Neutral to Buy. Airbnb shares closed at $125.49 on Tuesday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for PACCAR Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from $105 to $90. JP Morgan analyst Tami Zakaria downgraded the stock from Overweight to Neutral. PACCAR shares closed at $90.29 on Tuesday. <a href="https://www.benzinga.com/quote/PCAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners lowered NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) price target from $25 to $9. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. NeoGenomics shares settled at $6.58 on Tuesday. <a href="https://www.benzinga.com/quote/NEO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners cut Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) price target from $12 to $8. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Quanterix shares closed at $6.05 on Tuesday. <a href="https://www.benzinga.com/quote/QTRX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) price target from $15 to $8. HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating. Zynex shares closed at $2.23 on Tuesday.  <a href="https://www.benzinga.com/quote/ZYXI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup lowered the price target for Warby Parker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from $23 to $19. Citigroup analyst Paul Lejuez upgraded the stock from Sell to Neutral. Warby Parker shares settled at $15.80 on Tuesday. <a href="https://www.benzinga.com/quote/WRBY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank increased T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) price target from $275 to $277.5. Scotiabank analyst Maher Yaghi upgraded the stock from Sector Perform to Sector Outperform. T-Mobile US shares closed at $241.59 on Tuesday. <a href="https://www.benzinga.com/quote/TMUS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png" alt="" class="wp-image-894667" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30073519/image-231.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

ABNB

PCAR

QTRX

SBUX

TMUS

WRBY

ZYXI

Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

Needham analyst Mike Matson maintains AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Buy and lowers the price target from $51 to $44.

Needham Maintains Buy on AtriCure, Lowers Price Target to $44

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) raises FY2025 Adj EPS guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) analyst estimate. Affirms FY2025 sales outlook from $517.00 million-$527.00 million to $517.00 million-$527.00 million vs $522.79 million estimate.

AtriCure Raises FY2025 Adj EPS Guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) Est; Affirms FY2025 Sales Guidance of $517.00M-$527.00M vs $522.79M Est

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.23) by 39.13 percent. This is a 44 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $123.62 million which beat the analyst consensus estimate of $122.92 million by 0.57 percent. This is a 13.57 percent increase over sales of $108.85 million the same period last year.

AtriCure Q1 Adj. EPS $(0.14) Beats $(0.23) Estimate, Sales $123.62M Beat $122.92M Estimate

AEYE

AMSF

ARCB

ASTE

BBIO

BBVA

BGFV

CLVT

CSGP

ENSG

ENVA

ESRT

ETWO

FFIC

FICO

FOUR

FRST

FSLR

HLMN

HRZN

HSBC

HURN

INTZ

JAKK

LFUS

LGIH

Laboratory Corporation Of America Holdings

Earnings Scheduled For April 29, 2025

AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that AtriCure will report an earnings per share (EPS) of $-0.22. 
The announcement from AtriCure is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.07, leading to a 6.54% drop in the share price on the subsequent day.
Here's a look at AtriCure's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.19</td>
<td>-0.17</td>
<td>-0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.17</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>18.0%</td>
<td>-2.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745866944_0.png" alt="eps graph" />
<h3>Market Performance of AtriCure's Stock</h3>
Shares of AtriCure were trading at $33.4 as of April 25. Over the last 52-week period, shares are up 39.55%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Views on AtriCure</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on AtriCure.
Analysts have provided AtriCure with 13 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $53.15, suggesting a potential 59.13% upside.
<h3>Comparing Ratings with Competitors</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Conmed, Omnicell and QuidelOrtho, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Conmed, with an average 1-year price target of $72.2, suggesting a potential 116.17% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Omnicell, with an average 1-year price target of $45.33, suggesting a potential 35.72% upside.</li>
<li>Analysts currently favor an Neutral trajectory for QuidelOrtho, with an average 1-year price target of $43.67, suggesting a potential 30.75% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Conmed, Omnicell and QuidelOrtho, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AtriCure</td>
<td>Outperform</td>
<td>16.64%</td>
<td>$92.62M</td>
<td>-3.36%</td>
</tr>
<tr>
<td>Conmed</td>
<td>Neutral</td>
<td>5.78%</td>
<td>$198.34M</td>
<td>3.56%</td>
</tr>
<tr>
<td>Omnicell</td>
<td>Neutral</td>
<td>18.56%</td>
<td>$141.76M</td>
<td>1.28%</td>
</tr>
<tr>
<td>QuidelOrtho</td>
<td>Neutral</td>
<td>-4.69%</td>
<td>$326.10M</td>
<td>-5.78%</td>
</tr>
</tbody>
</table>

Key Takeaway:
AtriCure ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, AtriCure's performance is strong in terms of revenue and profit growth, but it lags behind in generating returns for its shareholders.
<h3>About AtriCure</h3>
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
<h3>AtriCure: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining AtriCure's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.64% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AtriCure's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.53% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.36%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): AtriCure's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.54%, the company may face hurdles in achieving optimal financial returns.
Debt Management: AtriCure's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ATRC/earnings">To track all earnings releases for AtriCure visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AtriCure Earnings Preview

Citizens Capital Markets analyst Daniel Stauder reiterates AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Market Outperform and maintains $60 price target.

Citizens Capital Markets Reiterates Market Outperform on AtriCure, Maintains $60 Price Target

Press Releases

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

AtriCure to Host Analyst & Investor Day on March 26, 2025

AtriCure to Announce First Quarter 2025 Financial Results

AtriCure Announces First Use of the AtriClip PRO-Mini® Device

AtriCure Reports First Quarter 2025 Financial Results

AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

AtriCure to Announce Second Quarter 2025 Financial Results

AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention

AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference

AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025

Comments

AtriCure

AtriCure (ATRC) Options

AtriCure (NASDAQ:ATRC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL